Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31246466 | 0.88 | KMT2A (0.59) | KMT2ATSHRMAPK1TACR1ERCC5 | |
| SCHEMBL14688342 | 0.85 | KMT2A (0.59) | KMT2ATSHRMAPK1TACR1ERCC5 | |
| SCHEMBL14688079 | 0.84 | KMT2A (0.44) | KMT2ATSHRMAPK1TACR1TDP1 | |
| SCHEMBL15343524 | 0.80 | KMT2A (0.67) | KMT2ATSHRMAPK1TACR1ERCC5 | |
| SCHEMBL19204050 | 0.80 | KMT2A (0.67) | KMT2ATSHRMAPK1TACR1ERCC5 | |
| SCHEMBL22096218 | 0.79 | KMT2A (0.41) | KMT2ATSHRMAPK1TACR1ERCC5 | |
| SCHEMBL16099241 | 0.79 | KMT2A (0.56) | KMT2ATSHRMAPK1TACR1ERCC5 | |
| SCHEMBL18650130 | 0.79 | NR4A1 (0.47) | KMT2ATSHRMAPK1TDP1HPGD | |
| SCHEMBL10269519 | 0.77 | KMT2A (0.63) | KMT2ATSHRMAPK1TACR1ERCC5 | |
| SCHEMBL20366867 | 0.77 | KMT2A (0.68) | KMT2ATSHRMAPK1ERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735384-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130040931-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011090911-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040931-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APH1B | KMT2A 1229/4885TSHR 3909/4885MAPK1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.